Mesenchymal stem cell (MSc) secretome: A possible therapeutic strategy for intensive-care COVID-19 patients

As an emerging global health challenge, COVID-19 requires international knowledge to reach novel possible therapeutic strategies, especially for intensive-care patients. During the early stages of infection, pneumocytes II are the primary infected cells, harming the respiratory system. We have previ...

Descripción completa

Detalles Bibliográficos
Autores principales: Deffune, Elenice, Prudenciatti, Aruã, Moroz, Andrei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252028/
https://www.ncbi.nlm.nih.gov/pubmed/32371362
http://dx.doi.org/10.1016/j.mehy.2020.109769
_version_ 1783539073078525952
author Deffune, Elenice
Prudenciatti, Aruã
Moroz, Andrei
author_facet Deffune, Elenice
Prudenciatti, Aruã
Moroz, Andrei
author_sort Deffune, Elenice
collection PubMed
description As an emerging global health challenge, COVID-19 requires international knowledge to reach novel possible therapeutic strategies, especially for intensive-care patients. During the early stages of infection, pneumocytes II are the primary infected cells, harming the respiratory system. We have previous evidence in murine models that MSc’s secretome can be used to treat pulmonary injuries induced with bleomycin, due to its content: growth factors, extracellular vesicles, and exosomes. We hypothesize and strongly recommend MSc secretome testing and production, in xenofree conditions, to be used as an alternative approach in SARS-Cov-2 patients in critical conditions.
format Online
Article
Text
id pubmed-7252028
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-72520282020-05-28 Mesenchymal stem cell (MSc) secretome: A possible therapeutic strategy for intensive-care COVID-19 patients Deffune, Elenice Prudenciatti, Aruã Moroz, Andrei Med Hypotheses Article As an emerging global health challenge, COVID-19 requires international knowledge to reach novel possible therapeutic strategies, especially for intensive-care patients. During the early stages of infection, pneumocytes II are the primary infected cells, harming the respiratory system. We have previous evidence in murine models that MSc’s secretome can be used to treat pulmonary injuries induced with bleomycin, due to its content: growth factors, extracellular vesicles, and exosomes. We hypothesize and strongly recommend MSc secretome testing and production, in xenofree conditions, to be used as an alternative approach in SARS-Cov-2 patients in critical conditions. Elsevier Ltd. 2020-09 2020-04-25 /pmc/articles/PMC7252028/ /pubmed/32371362 http://dx.doi.org/10.1016/j.mehy.2020.109769 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Deffune, Elenice
Prudenciatti, Aruã
Moroz, Andrei
Mesenchymal stem cell (MSc) secretome: A possible therapeutic strategy for intensive-care COVID-19 patients
title Mesenchymal stem cell (MSc) secretome: A possible therapeutic strategy for intensive-care COVID-19 patients
title_full Mesenchymal stem cell (MSc) secretome: A possible therapeutic strategy for intensive-care COVID-19 patients
title_fullStr Mesenchymal stem cell (MSc) secretome: A possible therapeutic strategy for intensive-care COVID-19 patients
title_full_unstemmed Mesenchymal stem cell (MSc) secretome: A possible therapeutic strategy for intensive-care COVID-19 patients
title_short Mesenchymal stem cell (MSc) secretome: A possible therapeutic strategy for intensive-care COVID-19 patients
title_sort mesenchymal stem cell (msc) secretome: a possible therapeutic strategy for intensive-care covid-19 patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252028/
https://www.ncbi.nlm.nih.gov/pubmed/32371362
http://dx.doi.org/10.1016/j.mehy.2020.109769
work_keys_str_mv AT deffuneelenice mesenchymalstemcellmscsecretomeapossibletherapeuticstrategyforintensivecarecovid19patients
AT prudenciattiarua mesenchymalstemcellmscsecretomeapossibletherapeuticstrategyforintensivecarecovid19patients
AT morozandrei mesenchymalstemcellmscsecretomeapossibletherapeuticstrategyforintensivecarecovid19patients

Ejemplares similares